A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers (NCT01460134) | Clinical Trial Compass
CompletedPhase 1
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
United States90 participantsStarted 2011-10
Plain-language summary
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18 years of age or older.
✓. Body Weight ≤ 120 kg.
✓. Histologic diagnosis of either a B-cell or T-cell hematologic malignancy known to express CD27 or one of the following solid tumors: metastatic melanoma, renal (clear) cell carcinoma, hormone-refractory prostate adenocarcinoma, ovarian cancer, colorectal adenocarcinoma or non-small cell lung cancer. For the solid tumor expansion cohorts, enrollment is limited to the following solid tumors: melanoma and renal cell carcinoma.
✓. Tumor must be recurrent or treatment refractory with no remaining alternative, approved therapy options, with the following exception: melanoma patients enrolled in the expansion phase must have previously received ipilimumab and, for patients with the BRAF V600E mutation, vemurafenib, or have been offered such therapies and refused, and patients must have progressive disease subsequent to previous therapies.
✓. Measurable or evaluable disease.
✓. Have adequate blood, bone marrow, liver and kidney function as determined by laboratory tests.
✓. If of childbearing potential (male or female), agree to practice an effective form of contraception during study treatment.
✓. Have little or no side effects remaining from prior cancer therapies.
Exclusion criteria
✕. Known prior primary or metastatic brain or meningeal tumors.
✕. Receiving treatment with immunosuppressive agents, including any systemic steroids.
What they're measuring
1
Characterize the adverse events associated with CDX-1127 administration
Timeframe: Safety follow up is 70 days from last dose.